EP300 and cardiac hypertrophy: Administration of 3.75 mg/kg anacardic acid improved cardiac hypertrophy through modulating histone acetylation (Li et al., 2019) by inhibiting the expression of p300 and p300/CBP-associated factor (PCAF), thereby reducing H3K9ac levels and normalizing the transcriptional activity of Mef2 (Li et al., 2019).